Genetic Insights for Drug Development in NAFLD.

[1]  E. Speliotes,et al.  17‐Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[2]  T. Berg,et al.  A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. , 2019, Journal of hepatology.

[3]  M. Karsdal,et al.  ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis , 2019, Hepatology.

[4]  M. Ziol,et al.  PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases , 2018, International journal of cancer.

[5]  Jonathan C. Cohen,et al.  HSD17B13 and Chronic Liver Disease in Blacks and Hispanics. , 2018, The New England journal of medicine.

[6]  Dermot F. Reilly,et al.  Phenome-wide association studies across large population cohorts support drug target validation , 2018, Nature Communications.

[7]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[8]  Antonio Felix Conde-Martin,et al.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.

[9]  D. Schlessinger,et al.  Genetic-Driven Druggable Target Identification and Validation. , 2018, Trends in genetics : TIG.

[10]  B. Neuschwander‐Tetri,et al.  Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2018, Hepatology.

[11]  Alexander E. Lopez,et al.  A Protein‐Truncating HSD17B13 Variant and Protection from Chronic Liver Disease , 2018, The New England journal of medicine.

[12]  M. Eslam,et al.  Genetics and epigenetics of NAFLD and NASH: Clinical impact. , 2018, Journal of hepatology.

[13]  B. Nordestgaard,et al.  Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals , 2018, European heart journal.

[14]  L. Elo,et al.  Hydroxysteroid (17β) dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  L. Carlsson,et al.  Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver , 2017, Journal of internal medicine.

[16]  B. Neuschwander‐Tetri,et al.  Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis , 2017, Hepatology.

[17]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[18]  Zhi-Sheng Jiang,et al.  TM6SF2: A novel target for plasma lipid regulation. , 2018, Atherosclerosis.

[19]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[20]  George Davey Smith,et al.  Recent Developments in Mendelian Randomization Studies , 2017, Current Epidemiology Reports.

[21]  Anurag Verma,et al.  Current Scope and Challenges in Phenome-Wide Association Studies , 2017, Current Epidemiology Reports.

[22]  Alexandra N. Schlein,et al.  Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease , 2017, Hepatology.

[23]  Luca Valenti,et al.  Mutant PNPLA3 I148M protein as pharmacological target for liver disease , 2017, Hepatology.

[24]  Jonathan C. Cohen,et al.  The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation , 2017, Hepatology.

[25]  G. Svegliati-Baroni,et al.  Fibronectin Type III Domain–Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease , 2017, The Journal of clinical endocrinology and metabolism.

[26]  S. Tsai,et al.  Liver Fat, Hepatic Enzymes, Alkaline Phosphatase and the Risk of Incident Type 2 Diabetes: A Prospective Study of 132,377 Adults , 2017, Scientific Reports.

[27]  H. Reeves,et al.  MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals , 2017, Scientific Reports.

[28]  N. Schork,et al.  Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis , 2017, The Journal of clinical investigation.

[29]  V. Wong,et al.  The membrane‐bound O‐acyltransferase domain‐containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B , 2017, Hepatology.

[30]  M. Trauner,et al.  The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells , 2017, Hepatology.

[31]  Carolina N. Perdigoto.  Mutations: Dawn of the Human Knockout Project , 2017, Nature Reviews Genetics.

[32]  D. Booth,et al.  IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis , 2017, Nature Genetics.

[33]  J. Ramaekers.  Drugs and Driving Research in Medicinal Drug Development. , 2017, Trends in pharmacological sciences.

[34]  Lisa Bastarache,et al.  Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. , 2017, Assay and drug development technologies.

[35]  Neil M Davies,et al.  Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities , 2017, bioRxiv.

[36]  Hynek Pikhart,et al.  PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study , 2017, The lancet. Diabetes & endocrinology.

[37]  T. Lam,et al.  Mendelian randomization estimates of alanine aminotransferase with cardiovascular disease: Guangzhou Biobank Cohort study , 2016, Human molecular genetics.

[38]  M. Pirmohamed,et al.  Genomics of Adverse Drug Reactions. , 2017, Trends in pharmacological sciences.

[39]  G. Leung,et al.  Liver Enzymes and Risk of Ischemic Heart Disease and Type 2 Diabetes Mellitus: A Mendelian Randomization Study , 2016, Scientific Reports.

[40]  Maren Preis,et al.  Printed Drug-Delivery Systems for Improved Patient Treatment. , 2016, Trends in pharmacological sciences.

[41]  M. Orho-Melander,et al.  The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. , 2016, Journal of hepatology.

[42]  Szilard Voros,et al.  Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. , 2016, The New England journal of medicine.

[43]  Hyejung Won,et al.  The road to precision psychiatry: translating genetics into disease mechanisms , 2016, Nature Neuroscience.

[44]  B. Bibby,et al.  The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[45]  T. Berg,et al.  MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C , 2016, Nature Communications.

[46]  J. Zucman‐Rossi,et al.  PNPLA3 gene in liver diseases. , 2016, Journal of hepatology.

[47]  D. Booth,et al.  Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes , 2016, Hepatology.

[48]  Christopher L. McClendon,et al.  Discovery of Novel 15-Lipoxygenase Activators To Shift the Human Arachidonic Acid Metabolic Network toward Inflammation Resolution. , 2016, Journal of medicinal chemistry.

[49]  N. Turner,et al.  Repurposing Drugs to Target the Diabetes Epidemic. , 2016, TIPS - Trends in Pharmacological Sciences.

[50]  Dermot F. Reilly,et al.  The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. , 2016, Gastroenterology.

[51]  R. W. Hansen,et al.  Journal of Health Economics , 2016 .

[52]  Heidi Ledford,et al.  AstraZeneca launches project to sequence 2 million genomes , 2016, Nature.

[53]  C. Tripodo,et al.  MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[54]  T. Yamanaka,et al.  Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. , 2016, Gastroenterology.

[55]  Dana C. Crawford,et al.  Unravelling the human genome–phenome relationship using phenome-wide association studies , 2016, Nature Reviews Genetics.

[56]  Thomas Berg,et al.  FibroGENE: A gene-based model for staging liver fibrosis. , 2016, Journal of hepatology.

[57]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[58]  J. George,et al.  Genetic and epigenetic mechanisms of NASH , 2016, Hepatology International.

[59]  N. Schork,et al.  Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. , 2015, Gastroenterology.

[60]  K. Huse,et al.  A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis , 2015, Nature Genetics.

[61]  J. George,et al.  Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution , 2015, Seminars in Liver Disease.

[62]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[63]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .

[64]  Junqing Wang,et al.  Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease , 2015, Journal of neuroscience research.

[65]  Laurent Dollé,et al.  Pharmacological chaperone therapies: Can aldehyde dehydrogenase activator make us healthier? , 2015, Journal of hepatology.

[66]  Sara Ballouz,et al.  Novel therapeutics for coronary artery disease from genome-wide association study data , 2015, BMC Medical Genomics.

[67]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[68]  S. Friedman,et al.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop , 2015, Hepatology.

[69]  V. Wong,et al.  Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease , 2015, Nature Communications.

[70]  Vincenzo Forgetta,et al.  Mendelian randomisation applied to drug development in cardiovascular disease: a review , 2014, Journal of Medical Genetics.

[71]  K. Clément,et al.  TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.

[72]  A. Hamsten,et al.  TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content , 2014, Proceedings of the National Academy of Sciences.

[73]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[74]  PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells , 2014, Human molecular genetics.

[75]  He Zhang,et al.  Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk , 2014, Nature Genetics.

[76]  Anne Tybjærg-Hansen,et al.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.

[77]  Jun S. Liu,et al.  Genetics of rheumatoid arthritis contributes to biology and drug discovery , 2013 .

[78]  Sahdeo Prasad,et al.  Cancer drug discovery by repurposing: teaching new tricks to old dogs. , 2013, Trends in pharmacological sciences.

[79]  J. Arrowsmith,et al.  Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.

[80]  D. Altshuler,et al.  Validating therapeutic targets through human genetics , 2013, Nature Reviews Drug Discovery.

[81]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[82]  Hongyu Zhao,et al.  Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents , 2012, Hepatology.

[83]  E. Kuipers,et al.  Anti‐inflammatory actions of phosphatidylinositol , 2011, European journal of immunology.

[84]  Udo Hoffmann,et al.  Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits , 2011, PLoS genetics.

[85]  J. George,et al.  Animal models of nonalcoholic fatty liver disease , 2011, Nature Reviews Gastroenterology &Hepatology.

[86]  D. Conen,et al.  Use of a Mendelian randomization approach to assess the causal relation of gamma-Glutamyltransferase with blood pressure and serum insulin levels. , 2010, American journal of epidemiology.

[87]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[88]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[89]  Nick V. Grishin,et al.  A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis , 2009, The Journal of Biological Chemistry.

[90]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[91]  Nicola L. Beer,et al.  The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver , 2009, Human molecular genetics.

[92]  F. Matschinsky,et al.  Assessing the potential of glucokinase activators in diabetes therapy , 2009, Nature Reviews Drug Discovery.

[93]  S. Grundy,et al.  Ethnic differences in hepatic steatosis: An insulin resistance paradox? , 2009, Hepatology.

[94]  R. Collins,et al.  Common variants at 30 loci contribute to polygenic dyslipidemia , 2009, Nature Genetics.

[95]  R. Murphy,et al.  Lysophospholipid Acyltransferases and Arachidonate Recycling in Human Neutrophils* , 2008, Journal of Biological Chemistry.

[96]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[97]  A. Nakajima,et al.  Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD) , 2007, Gut.

[98]  Marcia M. Nizzari,et al.  Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels , 2007, Science.

[99]  G. Abecasis,et al.  A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants , 2007, Science.

[100]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[101]  D. Redelmeier,et al.  Translation of research evidence from animals to humans. , 2006, JAMA.

[102]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[103]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[104]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[105]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[106]  S. Baulande,et al.  Adiponutrin : a transmembrane protein corresponding to a novel dietary-and obesity-linked mRNA specifically expressed in the adipose lineage , 2001 .